ClinicalTrials.gg
CompletedNCT02282761Updated Oct 2, 2025Results posted

A Trial to Assess the Antipsychotic Efficacy of ITI-007

A Phase 3 interventional study of ITI-007 and Placebo in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
3rd of 12
450 · median 66
Started
2014
with 1 other
Phase 3
5 of 12
2 open now
Registered
2nd of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
  • experiencing an acute exacerbation of psychosis

Exclusion criteria

Exclusion Criteria:

  • any subject unable to provide
  • any female subject who is pregnant or breast-feeding
  • any subject judged to be medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Lumateperone 28 mg (ITI-007 40 mg Tosylate)

    Lumateperone 28 mg (ITI-007 40 mg Tosylate) administered orally as formulated capsules once daily for 28 days

    Drug: ITI-007

  • Experimental
    Lumateperone 42 mg (ITI-007 60 mg Tosylate)

    Lumateperone 42 mg (ITI-007 60 mg Tosylate) administered orally as formulated capsules once daily for 28 days

    Drug: ITI-007

  • Placebo comparator
    Placebo

    Placebo administered orally as formulated capsules once daily for 28 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: 28 days

Secondary outcomes

  1. Change From Baseline to Day 28 in Clinical Global Impressions-Severity of Illness Scale

    The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."

    Time frame: 28 days

07

Results

Posted Oct 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Started150150149
Completed120128111
Not completed302238
Withdrew: Death001
Withdrew: Adverse event620
Withdrew: Lack of efficacy11617
Withdrew: Lost to follow-up221
Withdrew: Physician decision002
Withdrew: Withdrawal by subject81016
Withdrew: Other321

Outcome measures

PrimaryChange From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
28 days
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score-12.9 ± 1.27-14.5 ± 1.25-10.3 ± 1.32
Statistical analysis
  • Lumateperone 28 mg (ITI-007 40 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.182 · Least squares mean difference: -2.6 · 95% CI -6.17 to 1.05
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.045 · Least squares mean difference: -4.2 · 95% CI -7.75 to -0.60
SecondaryChange From Baseline to Day 28 in Clinical Global Impressions-Severity of Illness Scale

The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."

Time frame:
28 days
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 28 in Clinical Global Impressions-Severity of Illness Scale
units on a scaleLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Change From Baseline to Day 28 in Clinical Global Impressions-Severity of Illness Scale-0.8 ± 0.08-0.8 ± 0.07-0.5 ± 0.08
Statistical analysis
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.045 · Least squares mean difference: -0.3 · 95% CI -0.54 to -0.12

Adverse events

Collected over From signing ICF until end of study procedures (~49 days), including 28 days of double-blind treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 28 mg (ITI-007 40 mg Tosylate)0/150 (0%)1/150 (0.7%)55/150 (36.7%)
Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/150 (0%)0/150 (0%)70/150 (46.7%)
Placebo1/149 (0.7%)1/149 (0.7%)41/149 (27.5%)
Most frequent serious events
Most frequent serious events
EventLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
AsthmaRespiratory, thoracic and mediastinal disorders0/1500/1501/149
ConvulsionNervous system disorders1/1500/1500/149
Most frequent other events
Most frequent other events
EventLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
HeadacheNervous system disorders24/15029/15022/149
SomnolenceNervous system disorders17/15026/1506/149
SedationNervous system disorders14/15019/1508/149
NauseaGastrointestinal disorders7/15016/15011/149
Dry MouthGastrointestinal disorders9/15011/1507/149
DizzinessNervous system disorders7/15010/1506/149
ConstipationGastrointestinal disorders6/15010/1504/149
FatigueNervous system disorders7/1508/1502/149

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean43.5 ± 10.0842.4 ± 10.3041.4 ± 10.2942.4 ± 10.23
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Female374026103
Male113110123346
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
White423342117
Black or African American9410896298
Asian6118
Other881026
Positive and Negative Syndrome Scale (PANSS) total score
Positive and Negative Syndrome Scale (PANSS) total score(units on a scale)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean89.2 ± 10.1390.2 ± 9.5890.6 ± 11.2690.0 ± 10.34
08

Study locations

11 sites
  • Clinical Site
    Little Rock, Arkansas, United States
  • Clinical Site
    Springdale, Arkansas, United States
  • Clinical Site
    Escondido, California, United States
  • Clinical Site
    Garden Grove, California, United States
  • Clinical Site
    Long Beach, California, United States
  • Clinical Site
    San Diego, California, United States
  • Clinical Site
    Fort Lauderdale, Florida, United States
  • Clinical Site
    Rockville, Maryland, United States
  • Clinical Site
    St Louis, Missouri, United States
  • Clinical Site
    Marlton, New Jersey, United States
  • Clinical Site
    Austin, Texas, United States
09

References and documents

Publications

  • Citrome L, Durgam S, Edwards JB, Davis RE. Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J Clin Psychiatry. 2023 Mar 6;84(2):22r14631. doi: 10.4088/JCP.22r14631. PubMed 36883881 ↗
  • Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Apr 1;77(4):349-358. doi: 10.1001/jamapsychiatry.2019.4379. PubMed 31913424 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jul 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2025, 10 years 3 months after primary completion. A results delay was requested in Mar 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 4, 2014
Start
Nov 2014
Primary completionActual
Jul 2015
CompletionActual
Sep 2015
Results delay requested
Mar 9, 2017
Results first posted
Oct 2, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02282761
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Nov 2014
Primary completion
Jul 2015
Completion
Sep 2015
Results posted
Oct 2, 2025
Last update
Oct 2, 2025

Study contacts

Kimberly Vanover, Ph.D.
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion